Revelation Biosciences (NASDAQ:REVB – Get Free Report) and Athersys (NASDAQ:ATHX – Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, risk, dividends, institutional ownership, profitability and analyst recommendations.
Valuation & Earnings
This table compares Revelation Biosciences and Athersys”s revenue, earnings per share (EPS) and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Revelation Biosciences | N/A | N/A | -$120,000.00 | ($30.91) | -0.03 |
Athersys | $146,000.00 | 5.71 | -$72.53 million | ($2.03) | -0.01 |
Revelation Biosciences has higher earnings, but lower revenue than Athersys. Revelation Biosciences is trading at a lower price-to-earnings ratio than Athersys, indicating that it is currently the more affordable of the two stocks.
Risk and Volatility
Analyst Ratings
This is a breakdown of current recommendations and price targets for Revelation Biosciences and Athersys, as provided by MarketBeat.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Revelation Biosciences | 0 | 0 | 0 | 0 | N/A |
Athersys | 0 | 0 | 0 | 0 | N/A |
Institutional and Insider Ownership
12.8% of Revelation Biosciences shares are held by institutional investors. Comparatively, 19.4% of Athersys shares are held by institutional investors. 0.2% of Revelation Biosciences shares are held by insiders. Comparatively, 0.0% of Athersys shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Profitability
This table compares Revelation Biosciences and Athersys’ net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
Revelation Biosciences | N/A | -152.41% | -74.43% |
Athersys | N/A | N/A | -223.03% |
Summary
Athersys beats Revelation Biosciences on 5 of the 9 factors compared between the two stocks.
About Revelation Biosciences
Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease. The company was founded in 2020 and is based in San Diego, California.
About Athersys
Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. The company's lead platform product includes MultiStem cell therapy, an allogeneic stem cell product for the treatment of patients suffering from neurological damage from an ischemic stroke, as well as for acute respiratory distress syndrome, trauma complications, HSC transplant support, and other indications. It also develops MultiStem cell therapy to promote tissue repair and healing for animal patients. The company has license and collaboration agreements with Healios K.K. to develop and commercialize MultiStem cell therapy for ischemic stroke, acute respiratory distress syndrome, and ophthalmological indications, as well as for the treatment of liver, kidney, pancreas, and intestinal tissue diseases; and the University of Minnesota to develop MultiStem cell therapy platform. The company was founded in 1995 and is headquartered in Cleveland, Ohio.
Receive News & Ratings for Revelation Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revelation Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.